|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-5-25
|
|
pubmed:abstractText |
CYP17A1 is currently a target for total androgen blockade in advanced prostate cancer (CaP) patients. After castration, or removal of testicular androgens, CYP17A1 can act as a rate-limiting enzyme in androgen synthesis from cholesterol or other adrenal precursors within the tumor microenvironment ultimately contributing to disease progression. Herein we provide evidence that CYP17A1 could also be a mediator of cell-to-cell communication within the CaP tumor microenvironment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1097-0045
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
928-37
|
|
pubmed:meshHeading |
pubmed-meshheading:19267349-Adrenal Cortex Neoplasms,
pubmed-meshheading:19267349-Androgens,
pubmed-meshheading:19267349-Cell Communication,
pubmed-meshheading:19267349-Cell Line, Tumor,
pubmed-meshheading:19267349-Cell Polarity,
pubmed-meshheading:19267349-Cholesterol,
pubmed-meshheading:19267349-Disease Progression,
pubmed-meshheading:19267349-Enzyme Activation,
pubmed-meshheading:19267349-Exosomes,
pubmed-meshheading:19267349-Humans,
pubmed-meshheading:19267349-Kidney,
pubmed-meshheading:19267349-Male,
pubmed-meshheading:19267349-Microsomes, Liver,
pubmed-meshheading:19267349-NADPH-Ferrihemoprotein Reductase,
pubmed-meshheading:19267349-Orchiectomy,
pubmed-meshheading:19267349-Prostatic Neoplasms,
pubmed-meshheading:19267349-Steroid 17-alpha-Hydroxylase
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer.
|
|
pubmed:affiliation |
Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada.
|
|
pubmed:publicationType |
Journal Article
|
